GPI Valuation
Is Z44 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of Z44 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Z44 (€11.14) is trading below our estimate of fair value (€13.44)
Significantly Below Fair Value: Z44 is trading below fair value, but not by a significant amount.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for Z44?
Key metric: As Z44 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is Z44's PE Ratio? | |
|---|---|
| PE Ratio | 36.2x |
| Earnings | €8.93m |
| Market Cap | €323.83m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.3x |
| Enterprise Value/EBITDA | 9.8x |
| PEG Ratio | 1x |
Price to Earnings Ratio vs Peers
How does Z44's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 24.5x | ||
COP CompuGroup Medical SE KGaA | 28.9x | 32.9% | €726.9m |
NXU Nexus | 44.2x | 17.1% | €1.2b |
M3V MeVis Medical Solutions | 7.8x | n/a | €45.1m |
AJ91 DocCheck | 17.2x | n/a | €42.1m |
Z44 GPI | 36.2x | 35.2% | €323.8m |
Price-To-Earnings vs Peers: Z44 is expensive based on its Price-To-Earnings Ratio (36.2x) compared to the peer average (24.5x).
Price to Earnings Ratio vs Industry
How does Z44's PE Ratio compare vs other companies in the European Healthcare Services Industry?
| 2 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 2 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: Z44 is expensive based on its Price-To-Earnings Ratio (36.2x) compared to the European Healthcare Services industry average (18.6x).
Price to Earnings Ratio vs Fair Ratio
What is Z44's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 36.2x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate Z44's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €11.14 | €16.57 +48.7% | 11.3% | €19.10 | €14.60 | n/a | 3 |
| Nov ’25 | €11.72 | €16.57 +41.4% | 11.3% | €19.10 | €14.60 | n/a | 3 |
| Oct ’25 | €12.92 | €16.57 +28.2% | 11.3% | €19.10 | €14.60 | n/a | 3 |
| Sep ’25 | €11.90 | €16.37 +37.5% | 9.9% | €18.50 | €14.60 | n/a | 3 |
| Aug ’25 | n/a | €16.37 0% | 9.9% | €18.50 | €14.60 | n/a | 3 |
| Jul ’25 | n/a | €16.37 0% | 9.9% | €18.50 | €14.60 | n/a | 3 |
| Jun ’25 | n/a | €16.37 0% | 9.9% | €18.50 | €14.60 | n/a | 3 |
| May ’25 | n/a | €16.30 0% | 10.0% | €18.50 | €14.60 | n/a | 3 |
| Apr ’25 | n/a | €15.20 0% | 14.2% | €17.50 | €12.30 | n/a | 3 |
| Mar ’25 | n/a | €15.20 0% | 14.2% | €17.50 | €12.30 | n/a | 3 |
| Feb ’25 | n/a | €15.20 0% | 14.2% | €17.50 | €12.30 | n/a | 3 |
| Jan ’25 | n/a | €15.20 0% | 14.2% | €17.50 | €12.30 | n/a | 3 |
| Dec ’24 | n/a | €15.20 0% | 14.2% | €17.50 | €12.30 | n/a | 3 |
| Nov ’24 | n/a | €15.20 0% | 14.2% | €17.50 | €12.30 | €11.72 | 3 |
| Oct ’24 | n/a | €16.83 0% | 4.4% | €17.50 | €15.80 | €12.92 | 3 |
| Sep ’24 | n/a | €16.83 0% | 4.4% | €17.50 | €15.80 | €11.90 | 3 |
| Aug ’24 | n/a | €16.77 0% | 4.1% | €17.30 | €15.80 | n/a | 3 |
| Jul ’24 | n/a | €16.77 0% | 4.1% | €17.30 | €15.80 | n/a | 3 |
| Jun ’24 | n/a | €16.77 0% | 4.1% | €17.30 | €15.80 | n/a | 3 |
| May ’24 | n/a | €17.33 0% | 0.7% | €17.50 | €17.20 | n/a | 3 |
| Apr ’24 | n/a | €17.43 0% | 0.5% | €17.50 | €17.30 | n/a | 3 |
| Mar ’24 | n/a | €17.63 0% | 1.1% | €17.90 | €17.50 | n/a | 3 |
| Feb ’24 | n/a | €18.03 0% | 4.2% | €19.10 | €17.50 | n/a | 3 |
| Jan ’24 | n/a | €18.03 0% | 4.2% | €19.10 | €17.50 | n/a | 3 |
| Dec ’23 | n/a | €17.97 0% | 4.5% | €19.10 | €17.30 | n/a | 3 |
| Nov ’23 | n/a | €18.47 0% | 8.2% | €20.60 | €17.30 | n/a | 3 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
LNA Santé
€244.4m
Engages in the management and operation of health establishments.
2N3
€23.25
7D
-6.1%
1Y
16.0%
Shandong Weigao Group Medical Polymer
HK$20.1b
Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.
UK2
HK$0.52
7D
-1.0%
1Y
-38.8%
OrbusNeich Medical Group Holdings
HK$3.4b
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States.
Q8T
HK$0.51
7D
12.2%
1Y
-43.3%